The effect of zinc on the treatment and clinical course of patients with SARS-cov2 (COVID-19)

INTERVENTION: Intervention 1: Intervention group: Includes 40 patients with COVID‐19 which for 5 days, who are given two 200 mg hydroxychloroquine sulfate tablets every 12 hours on the first day and then 200 mg every 12 hours. In addition to the above, zinc tablets with a dose of 220 mg twice a day orally during the patient's hospitalization will be prescribed. Intervention 2: Control group: Includes 40 patients with COVID‐19 which for 5 days, who are given two 200 mg hydroxychloroquine sulfate tablets every 12 hours on the first day and then 200 mg every 12 hours. CONDITION: SARS‐cov2(COVID‐19). ; COVID‐19, virus identified U07.1 PRIMARY OUTCOME: Clinical response. Timepoint: During hospitalization. Method of measurement: Cessation of fever, improvement of shortness of breath, reduction of cough, blood oxygenation (SaO2) and hemodynamic parameters. Hospital stay. Timepoint: During hospitalization. Method of measurement: Count the number of hospital days to improve clinical symptoms. Mortality. Timepoint: During hospitalization. Method of measurement: Count the number of dead patients. INCLUSION CRITERIA: 18 years of age or older Diagnosis of COVID‐19 by RT PCR and CT scan of the lungs Blood oxygen levels are between 90 and 93 percent Breathing rate between 20 and 24 per minute Heart rate between 100 and 130 beats per minute